Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Sep 26, 2022 9:37pm
123 Views
Post# 34988333

RE:RE:RE:RE:RE:RE:RE:RE:RE:New corporate presentation

RE:RE:RE:RE:RE:RE:RE:RE:RE:New corporate presentationI can't find anything explaining the sudden increase interest but it is not what JFM suggested as many of their previous PRs do mention business updates.
I am not even sure the trading was solely from the retail but they added 50 or more watchers on Stocktwits which are usually retail. I do agree the current undervaluation is due lack of belief in the prospect of THTX's commercial and R&D operations my issue with their marketing approach is targeting only institutional investors which is so unnecessary and frustrating that me it is and been a missed opportunity when the retail investors are still a big part of the investment community. I started a business last year in a competitive space, we spend heavily on the marketing from the beginning, google, social media platforms, pulling out construction permits
palinc2000 wrote:

How can you tell the trading today in the US was from retail? 

I really thought that thru IR and other sources some investors have finally realized that the market cap did not even represent the value of existing legacy drug sales So the current SP does not take into account any increase in legacy drugs sales nor any potential positive development in the pipeline.

No downside and only upsides is a great investment thesis if you concur with that opinion

Why today?
I think it has been in the works for the past few weeks

 

 

scarlet1967 wrote:

 

2790bafc-6443-4aed-a90c-1cb2957c3330

2790bafc-6443-4aed-a90c-1cb2957c3330

 

https://www.theratech.com/static-files/8d86c08a-229e-4e9c-8ad2-ef353b8a4fbf

 

“Part 1 of the study is currently open to recruitment only in the USA.  Once MTD, RD and safety are established, part 2 (expansion) will open in sites in the USA, UK, and Europe.”

 

https://www.theratech.com/medicines-pipeline/pipeline-and-science/oncology/clinical-trials

 

I can’t see anything new apart from SP and market cap.

I don’t look often at the website but there is a patient information page for Oncology , Hepatology which might not be new?

 

https://www.theratech.com/medicines-pipeline/pipeline-and-science/oncology/patient-need

 

https://www.theratech.com/medicines-pipeline/pipeline-and-science/hepatology/patient-need

 

Even mentioning opening sites in the USA, UK and Europe might not be new but they are there so it will be interesting when and how many more sites if any will start enrolling. The intraday volume increased significantly today and now there are more than there are more than 1000 followers on Stocktwits which must be record as long as I remember. Both are positive developments in my opinion so a bit more exposure, more liquidity, less volatility etc. Hopefully this is the start of an ongoing trend going forward. 

I have said it many and too few times don’t underestimate the power of the retail investors!

 





<< Previous
Bullboard Posts
Next >>